Q1 FY2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: Galmed Pharma(GLMD) the Revenue is 0 (--%), Meet estimate;the EBIT is -2.044 M (-61.71%), Beat estimate;the EPS is -0.29 (+53.23%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.00B--
0.00B--
0.00B--%
EBITExceed expectations
-0.00B61.71%
-0.00B99.92%
+0.00B38.21%
EPSExceed expectations
-0.2953.23%
-0.3838.71%
+0.090014.52%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf